Tower Research Capital LLC (Trc) Janux Therapeutics, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $4.07 Billion
- Q1 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 1,259 shares of JANX stock, worth $52,739. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,259
Previous 1,768
28.79%
Holding current value
$52,739
Previous $18,000
161.11%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding JANX
# of Institutions
123Shares Held
25.3MCall Options Held
92KPut Options Held
161K-
Orbimed Advisors LLC San Diego, CA4.28MShares$179 Million3.62% of portfolio
-
Bvf Inc San Francisco, CA2.92MShares$122 Million3.29% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.78MShares$116 Million0.2% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.35MShares$98.5 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X01.97MShares$82.3 Million0.04% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.75B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...